SGLT2 territory. 3 years. still a coin flip.
Company: Boehringer Ingelheim
Tags: field, strategy, quota
cant out-data AZ because they have equivalent outcomes data. cant out-price because its formulary. only lever is showing up more than them. EMPEROR-Reduced in HFrEF is where I find any separation. granular beats broad every time
13 upvotes · 5 comments